These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 33455015)

  • 1. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
    Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
    APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
    Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
    Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
    Webb JR; Milne K; Kroeger DR; Nelson BH
    Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
    Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
    J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
    Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
    Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma.
    Böhm S; Montfort A; Pearce OM; Topping J; Chakravarty P; Everitt GL; Clear A; McDermott JR; Ennis D; Dowe T; Fitzpatrick A; Brockbank EC; Lawrence AC; Jeyarajah A; Faruqi AZ; McNeish IA; Singh N; Lockley M; Balkwill FR
    Clin Cancer Res; 2016 Jun; 22(12):3025-36. PubMed ID: 27306793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordance of PD-L1 expression in primary and metastatic ovarian high-grade serous carcinoma and its correlation with CD8 + tumor-infiltrating lymphocytes and patient prognosis.
    Zhang T; Zhou X; Zhang X; Niu S; Chen H; Zhou F
    Virchows Arch; 2023 Apr; 482(4):755-766. PubMed ID: 36806916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma.
    Martin de la Fuente L; Westbom-Fremer S; Arildsen NS; Hartman L; Malander S; Kannisto P; Måsbäck A; Hedenfalk I
    Virchows Arch; 2020 Jul; 477(1):83-91. PubMed ID: 31980961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
    Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
    Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
    Wan C; Keany MP; Dong H; Al-Alem LF; Pandya UM; Lazo S; Boehnke K; Lynch KN; Xu R; Zarrella DT; Gu S; Cejas P; Lim K; Long HW; Elias KM; Horowitz NS; Feltmate CM; Muto MG; Worley MJ; Berkowitz RS; Matulonis UA; Nucci MR; Crum CP; Rueda BR; Brown M; Liu XS; Hill SJ
    Cancer Res; 2021 Jan; 81(1):158-173. PubMed ID: 33158814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
    D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C
    Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
    Smazynski J; Hamilton PT; Thornton S; Milne K; Wouters MCA; Webb JR; Nelson BH
    Gynecol Oncol; 2020 Jul; 158(1):167-177. PubMed ID: 32446718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer.
    Fucikova J; Rakova J; Hensler M; Kasikova L; Belicova L; Hladikova K; Truxova I; Skapa P; Laco J; Pecen L; Praznovec I; Halaska MJ; Brtnicky T; Kodet R; Fialova A; Pineau J; Gey A; Tartour E; Ryska A; Galluzzi L; Spisek R
    Clin Cancer Res; 2019 Aug; 25(15):4820-4831. PubMed ID: 31076549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status.
    Whitehair R; Peres LC; Mills AM
    Int J Gynecol Pathol; 2020 Nov; 39(6):558-566. PubMed ID: 31851060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
    Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
    Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
    Lo CS; Sanii S; Kroeger DR; Milne K; Talhouk A; Chiu DS; Rahimi K; Shaw PA; Clarke BA; Nelson BH
    Clin Cancer Res; 2017 Feb; 23(4):925-934. PubMed ID: 27601594
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.
    Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
    Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.